News
$Mesoblast (MESO.US)$ FDA Grants Mesoblast's Revascor Regenerative Medicine Advanced Therapy Designation In Children With Congenital Heart DiseaseBenzinga· 13 mins agoMesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the United States Food and Drug Administration (FDA) has granted its second generation allogeneic, STRO3-immunoselected, and industrially manufactured stromal cell therapy Revascor (rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) designation following submission of results from the randomized controlled trial in children with hypoplastic left heart syndrome (HLHS), a potentially life threatening congenital heart condition.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Aariya : what is that mean vaccine approved or something else?
Trytosaveabit OP Aariya : In lay terms! The FDA says they can start treating children with their medication!
101674396 : But .. still dropping the price!!!
Trytosaveabit OP 101674396 : The news came out after market close! Let’s see if it brings volume tomorrow? GL
101674396 Trytosaveabit OP : Yes. but MSB (AUS) now drop so deeply
Trytosaveabit OP 101674396 : Could be short attack?
stderr Trytosaveabit OP : ibkr says zero for meso and msb on asx
Aariya Trytosaveabit OP : its look like short attack than long term buyer enter hope it pick up tomorrow